Biomedcode participates at INFRAFRONTIER2020 Kick-Off meeting, April 24-25th in MunichINFRAFRONTIER aims to build a world-class research infrastructure that provides the biomedical research community with the tools needed to...
10 APR 2017
Select the type of mice you are interested in.
Therapeutic Areas - Animal models
21 JUL 2017
JANSSEN announces U.S. FDA approval of TREMFYA™ (GUSELKUMAB), the first approved biologic that selectively blocks interleukin (IL)-23, for the treatment of moderate-to-severe plaque psoriasisTREMFYA™ is the first and only biologic approved that selectively blocks interleukin (IL)-23. Seven out of ten patients receiving...
FAQ - Top 10 Questions
Biomedcode is modeling human inflammatory conditions:
Client Testimonials - What our clients say about us
We have several collaborations with Biomedcode, their scientific and efficient experiment schedules made each collaboration accomplished according...Quote from Biopharmaceutical branch of a leading pharmaceutical company, China
Events and Webinars
Biomedcode was founded in 2006, as a spin-off of the Biomedical Sciences Research Center “Alexander Fleming”
Biomedcode has extensive expertise & scientific excellence in inflammatory & autoimmune animal disease models
Our mouse models of arthritis were instrumental in proving the efficacy of anti-hTNF therapeutics in arthritis
Biomedcode’s clients include top 5 worldwide pharmaceutical companies
Targeted metabolic profiling of the Tg197 mouse model reveals itaconic acid as a marker of Rheumatoid Arthritis.Biomedcode coauthors a publication on the identification of a biomarker with translational value for the diagnosis & monitoring of rheumatoid...
Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept...Biomedcode's human TNF transgenic arthritis model, (Tg197), contributes to the non-clinical assessment of etanercept biosimilar GP2015 with...
Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.Biomedcode's mouse models offered the in vivo non-clinical proof validating the efficacy of a novel composite hydrogel tacrolimus formulation for...